AXSOME THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
AXSOME THERAPEUTICS, INC. (AXSM) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $27.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $27.63M, a 10.70% increase year-over-year.
- AXSOME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $23.91M, a 1.10% increase year-over-year.
- AXSOME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $23.44M, a 6.59% increase year-over-year.
- AXSOME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $24.95M, a 14.95% increase year-over-year.
- AXSOME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $95.30M, a 10.10% increase from fiscal 2024.
- AXSOME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $86.56M, a 32.44% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $65.36M, a 73.24% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $37.73M, a 81.35% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $27.63M 10-Q · filed 2026-08-10 | $51.53M derived: sum of 2 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $23.91M 10-Q · filed 2026-08-10 | |||||
| 2025-12-31 | $95.30M 10-K · filed 2026-02-23 | |||||
| 2025-09-30 | $23.44M 10-Q · filed 2025-11-03 | $48.40M derived: sum of 2 quarters · filed 2026-08-10 | $72.04M derived: sum of 3 quarters · filed 2026-08-10 | |||
| 2025-06-30 | $24.95M 10-Q · filed 2026-08-10 | $48.60M derived: sum of 2 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $23.65M 10-Q · filed 2026-08-10 | |||||
| 2024-12-31 | $86.56M 10-K · filed 2026-02-23 | |||||
| 2024-09-30 | $21.99M 10-Q · filed 2025-11-03 | $43.70M derived: sum of 2 quarters · filed 2025-11-03 | $64.23M derived: sum of 3 quarters · filed 2025-11-03 | |||
| 2024-06-30 | $21.71M 10-Q · filed 2025-11-03 | $42.24M derived: sum of 2 quarters · filed 2025-11-03 | ||||
| 2024-03-31 | $20.53M 10-Q · filed 2025-11-03 | |||||
| 2023-12-31 | $65.36M 10-K · filed 2026-02-23 | |||||
| 2023-09-30 | $17.24M 10-Q · filed 2024-11-12 | $33.16M derived: sum of 2 quarters · filed 2024-11-12 | $46.10M derived: sum of 3 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $15.92M 10-Q · filed 2024-11-12 | $28.86M derived: sum of 2 quarters · filed 2024-11-12 | ||||
| 2023-03-31 | $12.94M 10-Q · filed 2024-11-12 | |||||
| 2022-12-31 | $37.73M 10-K · filed 2025-02-18 | $37.73M 10-K · filed 2023-02-28 | ||||
| 2022-09-30 | $9.20M 10-Q · filed 2023-11-06 | $9.20M 10-Q · filed 2022-11-07 | $19.36M derived: sum of 2 quarters · filed 2023-11-06 | $26.96M derived: sum of 3 quarters · filed 2023-11-06 | ||
| 2022-06-30 | $10.16M 10-Q · filed 2023-11-06 | $10.16M 10-Q · filed 2022-08-09 | $17.76M derived: sum of 2 quarters · filed 2023-11-06 | |||
| 2022-03-31 | $7.60M 10-Q · filed 2023-11-06 | $7.60M 10-Q · filed 2022-05-02 | ||||
| 2021-12-31 | $20.80M 10-K · filed 2024-02-23 | $20.80M 10-K · filed 2022-03-01 | ||||
| 2021-09-30 | $5.73M 10-Q · filed 2022-11-07 | $11.18M derived: sum of 2 quarters · filed 2022-11-07 | $14.91M derived: sum of 3 quarters · filed 2022-11-07 | |||
| 2021-06-30 | $5.46M 10-Q · filed 2022-11-07 | $9.19M derived: sum of 2 quarters · filed 2022-11-07 | ||||
| 2021-03-31 | $3.73M 10-Q · filed 2022-11-07 | |||||
| 2020-12-31 | $14.76M 10-K · filed 2023-02-28 | |||||
| 2020-09-30 | $2.87M 10-Q · filed 2021-11-08 | $7.02M derived: sum of 2 quarters · filed 2021-11-08 | $9.15M derived: sum of 3 quarters · filed 2021-11-08 | |||
| 2020-06-30 | $4.15M 10-Q · filed 2021-11-08 | $6.28M derived: sum of 2 quarters · filed 2021-11-08 | ||||
| 2020-03-31 | $2.13M 10-Q · filed 2021-11-08 | |||||
| 2019-12-31 | $6.12M 10-K · filed 2022-03-01 | |||||
| 2019-09-30 | $1.16M 10-Q · filed 2020-11-05 | $2.04M derived: sum of 2 quarters · filed 2020-11-05 | $3.30M derived: sum of 3 quarters · filed 2020-11-05 | |||
| 2019-06-30 | $888.56K 10-Q · filed 2020-11-05 | $2.14M derived: sum of 2 quarters · filed 2020-11-05 | ||||
| 2019-03-31 | $1.26M 10-Q · filed 2020-11-05 | |||||
| 2018-12-31 | $1.75M 10-K · filed 2021-03-01 | |||||
| 2018-09-30 | $392.67K 10-Q · filed 2019-11-07 | $867.32K derived: sum of 2 quarters · filed 2019-11-07 | $1.40M derived: sum of 3 quarters · filed 2019-11-07 | |||
| 2018-06-30 | $474.66K 10-Q · filed 2019-11-07 | $1.01M derived: sum of 2 quarters · filed 2019-11-07 | ||||
| 2018-03-31 | $534.57K 10-Q · filed 2019-11-07 | |||||
| 2017-12-31 | $2.07M 10-K · filed 2020-03-12 | |||||
| 2016-12-31 | $2.03M 10-K · filed 2019-03-15 | |||||
| 2015-12-31 | $803.28K 10-K · filed 2018-03-07 | |||||
| 2014-12-31 | $376.81K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |